🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Unresectable or Metastatic Breast Cancer

Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer NCT06222879Phase 1, Phase 21 site📍 Changsha Shandong Suncadia Medicine Co., Ltd. · Tests: HRS-8080; SHR-A1811, HRS-8080; SHR-A2009, SHR-A2009; SHR-1316 Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer NCT05950945Phase 388 sites📍 Miami Beach📍 Tampa📍 Boston Daiichi Sankyo · Tests: Trastuzumab Deruxtecan A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337Phase 32 sites📍 Beijing📍 Guangzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Tests: SKB264, Nab-paclitaxel, Paclitaxel, Capecitabine A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) NCT07648914Phase 31 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, Albumin-Bound Paclitaxel, Paclitaxel, Capecitabine DESTINY Breast Respond HER2-(Ultra)Low Europe NCT05945732n/a216 sites📍 Graz📍 Graz📍 Innsbruck Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · Tests: Trastuzumab deruxtecan Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors NCT05372640Phase 17 sites📍 Los Angeles📍 Los Angeles📍 Los Angeles National Cancer Institute (NCI) · Tests: Abemaciclib, BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan NCT05573893n/a109 sites📍 Amberg📍 Ansbach📍 Apolda AstraZeneca Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer NCT06434064Phase 21 site📍 Buffalo Roswell Park Cancer Institute · Tests: Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Resonance Imaging A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC NCT07002177Phase 1, Phase 21 site📍 Shanghai Forward Pharmaceuticals Co., Ltd. · Tests: FWD1802, Palbociclib 125mg, Ribociclib 200Mg Oral Tablet, Abemaciclib 150 MG, Everolimus 10 mg A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors NCT07488676Phase 1, Phase 221 sites📍 Birmingham📍 Los Angeles📍 Miami Astellas Pharma Global Development, Inc. · Tests: ASP546C Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. NCT06590857Phase 1, Phase 231 sites📍 Phoenix📍 Irvine📍 San Diego RayzeBio, Inc. · Tests: RYZ101, Standard of Care Endocrine Therapy Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer NCT06167694Phase 1, Phase 22 sites📍 Beijing📍 Guangzhou Shandong Suncadia Medicine Co., Ltd. · Tests: HRS-8080; Dalpiciclib Isethionate Tablets A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors NCT06827613Phase 1, Phase 28 sites📍 Los Angeles📍 Los Angeles📍 Boston Marengo Therapeutics, Inc. · Tests: STAR0602, Sacituzumab Govitecan (SG) Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer NCT05111561Phase 14 sites📍 Boston📍 Boston📍 Galveston National Cancer Institute (NCI) · Tests: BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure, Biospecimen Collection, Computed Tomography A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) NCT06312176Phase 3259 sites📍 Chandler📍 Gilbert📍 Fullerton Merck Sharp & Dohme LLC · Tests: Sacituzumab tirumotecan, Pembrolizumab, Paclitaxel, Nab-paclitaxel, Capecitabine YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer NCT07461454Phase 31 site📍 Shanghai MediLink Therapeutics (Suzhou) Co., Ltd. · Tests: YL202, Eribulin, Capecitabine, Gemcitabine, Vinorelbine A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer NCT07497386Phase 21 site📍 Beijing Jiangsu HengRui Medicine Co., Ltd. · Tests: Trastuzumab Rezetecan for Injection, Trastuzumab Deruxtecan for Injection A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674Phase 117 sites📍 Duarte📍 Los Angeles📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-1607, Paclitaxel A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer NCT07389733Phase 1, Phase 22 sites📍 Dalian📍 Chengdu Shandong Suncadia Medicine Co., Ltd. · Tests: HRS-6208 Capsule, HRS-6209 Capsule, HRS-8080 Tablet, Fulvestrant injection, Letrozole tablets A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer NCT07299825Phase 21 site📍 Zhenzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Tests: A166 A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors NCT06555068Phase 1, Phase 21 site📍 Shanghai Jiangsu HengRui Medicine Co., Ltd. · Tests: HRS-6209 in Combination with Fulvestrant, HRS-6209 in Combination with HRS-1358, HRS-6209 in Combination with Letrozole… Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer NCT06727227n/a14 sites📍 Panagyurishte📍 Burgas📍 Plovdiv AstraZeneca · Tests: trastuzumab deruxtecan A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. NCT06064812Phase 1, Phase 222 sites📍 Hefei📍 Guangzhou📍 Huizhou Forward Pharmaceuticals Co., Ltd. · Tests: FWD1802 A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors NCT06493864Phase 11 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B16D1 BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer NCT05977036NA1 site📍 St Louis Washington University School of Medicine · Tests: DiviTum® TKa assay Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer NCT05098210Phase 11 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive NCT07413939Phase 2, Phase 3206 sites📍 Huntsville📍 Gilbert📍 San Francisco Hoffmann-La Roche · Tests: RO7771950, Tucatinib, Trastuzumab, Capecitabine A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer NCT06471205Phase 21 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, PD-1 Monoclonal Antibody Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors NCT05983432Phase 137 sites📍 Beverly Hills📍 Duarte📍 Orange SystImmune Inc. · Tests: BL-B01D1 Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer NCT06642545Phase 21 site📍 Beijing RemeGen Co., Ltd. · Tests: Disitamab Vedotin, RC148, Albumin-bound Paclitaxone, Toripalimab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy